Dec 16 (Reuters) - Japanese healthcare firm Taisho
Pharmaceutical Holdings Co Ltd 4581.T is said to be close to a
$1.6 billion deal for Bristol-Myers Squibb Co's BMY.N French
over-the-counter drugs business UPSA, Bloomberg reported on
Sunday, citing sources familiar with the matter.
An agreement for the consumer-health business could be
announced as soon as this week, according to the report https://bloom.bg/2QyHulF.
Bristol-Myers Squibb said in an email to Reuters that it
does not comment on rumors and speculation, adding that the
company is still considering options for the strategic review of
UPSA that was announced in June.
A Taisho spokesman said the company could not comment on the
report.
German drugmaker Stada STAGn.D and Italian healthcare
company Angelini were among the final bidders for Bristol-Myers'
UPSA unit, according to a Reuters report in November.
urn:newsml:reuters.com:*:nL8N1XJ9IA
(Reporting by Bhanu Pratap in Bengaluru; Additional reporting
by Philip George in Bengaluru; Editing by Sunil Nair)
((Bhanu.Pratap@thomsonreuters.com; (within U.S. +1 646 223
8780, outside U.S. +91 80 6749 3581);))